Vindesine and mitomycin C in metastatic breast cancer. A Southeastern Cancer Study Group Trial.
64 eligible women with previously treated metastatic breast cancer received mitomycin C plus vindesine chemotherapy. Dosage was based on investigators' estimate of patients' bone marrow reserve. There were 19 evaluable patients in the good marrow reserve category, with two complete and three partial responses (26%). In the poor marrow reserve category there were 29 evaluable patients with four partial responses (14%). The 26% response rate in patients with good marrow reserve is consistent with results obtained with this and similar combinations by other investigators.
Lyss
A P
AP
Division of Hematology/Oncology, Jewish Hospital, Washington University Medical Center, St. Louis, Mo.
Luedke
S L
SL
Einhorn
L
L
Luedke
D W
DW
Raney
M
M
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D009362:Neoplasm Metastasis; D014751:Vindesine / Q000008:administration & dosage
D008937:Mitomycins; D016685:Mitomycin; D014751:Vindesine